Wide Ranks

EW

Edwards Lifesciences Corporatio

72.07

Top Statistics
Market Cap 42 B Forward PE 29.17 Revenue Growth 8.90 %
Current Ratio 3.46 Trailing PE 27.83 Earnings Growth 716.10 %
Profit Margins 65.86 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 18.92 Enterprise / Revenue 6.15 Price To Sales Trailing12 Months 6.73
Profitability
Profit Margins 65.86 % Operating Margins 29.11 %
Balance Sheet
Total Cash 4 B Total Cash Per Share 7.54 Total Debt 706 M
Total Debt To Equity 7.35 Current Ratio 3.46 Book Value Per Share 16.18
All Measures
Short Ratio 134.00 % Message Board Id finmb_411220 Fax 949 250 2525
Shares Short Prior Month 8 M Return On Equity 0.1914 City Irvine
Uuid 8cdb36f4-8677-373d-bde5-dd7ead8c731e Previous Close 71.55 First Trade Date Epoch Utc 954 M
Book Value 16.18 Beta 1.12 Total Debt 706 M
Volume 2 M Price To Book 4.45 Last Split Date 1 B
Fifty Two Week Low 58.93 Total Cash Per Share 7.54 Total Revenue 6 B
Shares Short Previous Month Date 1 B Target Median Price 76.50 Max Age 86400
Recommendation Mean 2.34 Sand P52 Week Change 0.3133 Operating Margins 29.11 %
Target Mean Price 76.61 Net Income To Common 1 B Ask 72.09
Short Percent Of Float 0.0117 Implied Shares Outstanding 595 M Last Fiscal Year End 1 B
Trailing Peg Ratio 661.25 % Average Daily Volume10 Day 4 M Average Volume10days 4 M
Total Cash 4 B Next Fiscal Year End 1 B Revenue Per Share 10.50
Held Percent Insiders 0.0091 Ebitda Margins 32.50 % Trailing PE 27.83
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 71.55
Target Low Price 63.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 67.91
Open 71.32 Free Cashflow 1 B State CA
Dividend Yield 0.00 % Return On Assets 0.1065 Time Zone Short Name EST
Trailing Eps 2.59 Day Low 71.32 Address1 One Edwards Way
Shares Outstanding 589 M Price Hint 2 Target High Price 96.80
Website https://www.edwards.com 52 Week Change 0.0644 Average Volume 6 M
Earnings Quarterly Growth 697.80 % Forward Eps 2.45 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 270.40 % Last Split Factor 3:1
Regular Market Day High 72.63 Is_sp_500 True Profit Margins 65.86 %
Debt To Equity 7.35 Fifty Two Week High 96.12 Day High 72.63
Shares Short 6 M Regular Market Open 71.32 Industry Key medical-devices
Bid 72.15 Earnings Growth 716.10 % Enterprise To Revenue 6.15
Revenue Growth 8.90 % Shares Percent Shares Out 0.0116 Operating Cashflow 806 M
Currency USD Time Zone Full Name America/New_York Market Cap 42 B
Is_nasdaq_100 False Zip 92614 Quote Type EQUITY
Industry Medical Devices Long Name Edwards Lifesciences Corporation Regular Market Day Low 71.32
Held Percent Institutions 0.8594 Current Price 72.07 Enterprise To Ebitda 18.92
Financial Currency USD Current Ratio 3.46 Gross Margins 76.60 %
Industry Disp Medical Devices Number Of Analyst Opinions 28 Country United States
Float Shares 583 M Two Hundred Day Average 79.41 Ir Website http://ir.edwards.com/
Enterprise Value 38 B Price To Sales Trailing12 Months 6.73 Forward PE 29.17
Regular Market Volume 2 M Ebitda 2 B Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally.

It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve.

In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure.

The company distributes its products through a direct sales force and independent distributors.

Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.